Truist Securities Reiterates Rating on Insulet Corporation $PODD
Key Points
- Truist Securities now rates Insulet Corporation ($PODD) "buy" with a $219.00 target.
- The Street's average $PODD price target is $242.43 (Strong Buy).
- $PODD last traded around $148.14.
Truist Securities reiterated its rating on Insulet Corporation ($PODD) to a "buy" rating, with a price target of $219.00 in a recent research note.
Insulet Corporation ($PODD) Stock
Insulet Corporation Earnings
Analysts Set New Price Targets
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.